Brainstorm Cell Therapeutics Inc Share Price OTC Bulletin Board
Equities
US10501E2019
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 33.26M 2.77B |
---|---|---|---|---|---|
Net income 2024 * | -21M -1.75B | Net income 2025 * | -27M -2.25B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.74
x | P/E ratio 2025 * |
-1.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.64% |
Latest transcript on Brainstorm Cell Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 53 | 01/07/01 |
Alla Patlis
DFI | Director of Finance/CFO | 37 | 23/12/23 |
Chief Tech/Sci/R&D Officer | - | 12/22/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irit Arbel
FOU | Founder | 64 | 22/00/22 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06/14/06 |
Jacob Frenkel
CHM | Chairman | 81 | 30/20/30 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |